Company profile

Zura Bio Limited

Pipeline3 assets

tibulizumabZB-106 / IL-17A and BAFF / Bispecific dual-antagonist antibody / Autoimmune and Inflammatory Diseases
Hidradenitis suppurativaSystemic sclerosis
crebankitugZB-168 / IL-7Rα / Monoclonal antibody / Autoimmune and Inflammatory Diseases
Autoimmune and inflammatory conditions
torudokimabZB-880 / IL-33 / Monoclonal antibody / Autoimmune and Inflammatory Diseases
Autoimmune and inflammatory conditions

Latest news14 items

Jun 29, 2026

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE has exceeded the 80 participant enrollment

Enrollment • Phase 2Enrollment milestone Mon, Jun 29, 2026

May 14, 2026

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev. --(BUSINESS WIRE)--May 14, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

May 13, 2026

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

HENDERSON, Nev. --(BUSINESS WIRE)--May 13, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today

May 7, 2026

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated timelines Strengthened leadership team with key executive and Board appointments Completed an

May 4, 2026

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev. --(BUSINESS WIRE)--May 4, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

Mar 19, 2026

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027 Cash and cash

Mar 5, 2026

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 5, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today

Mar 2, 2026

Zura Bio to Participate in Upcoming Investor Conferences

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 2, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

Feb 27, 2026

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 27, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today

Feb 25, 2026

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 25, 2026-- Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced

Feb 24, 2026

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 24, 2026-- Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced

Feb 23, 2026

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 23, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and

Feb 4, 2026

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 4, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

Jan 21, 2026

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 21, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory